calanolide a
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002243)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCc1cc(=O)oc2c3c(c4c(c12)OC(C)(C)C=C4)O[C@H](C)[C@@H](C)[C@@H]3O- Mol. weight
- 370.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL270362 ↗
- ChEMBLCHEMBL267447 ↗
Also known as
- (+/-)-calanolide a
- (+/-)-calanolide a
- (+)-calanolide a
- (+)-calanolide a
- calanolide a
- calanolide a
- calanolide a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005120 | Phase 1 | Apr 1, 2000 | Sarawak MediChem Pharmaceuticals |
| NCT00002243 | Phase 1 | Nov 2, 1999 | Sarawak MediChem Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sarawak MediChem Pharmaceuticals | For profit | 2 | 2 | 1 | 1999 |
1 organizations
Page 1 / 1